Written edition
Science Corp.'s retinal chip clears EU approval ahead of Neuralink
The frontier is fragmenting into distinct moats today—regulatory, commercial, and geopolitical.
From brain-computer interfaces moving outside the skull to stablecoin rails for autonomous agents, the race is no longer just about innovation but who controls the path to market.
Science Corp. wins first EU approval for retinal BCI
Science Corp., led by Neuralink's former president, just secured EU regulatory clearance for its retinal implant—the first commercial brain-computer interface approval outside the brain itself. Unlike Neuralink's skull-penetrating implants, this chip sits on the retina and transmits signals to the visual cortex without brain surgery, which means lower risk and faster patient access. The approval reframes the BCI sector: vision restoration may reach patients years before cognitive interfaces do, and Science Corp. now holds a regulatory head start in the world's second-largest medical device market. For the field, it's proof that the shortest path to commercialization runs around the brain, not through it.
